Compare, Analyse Glenmark Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs TEVA PHARMA (Israel) - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
TEVA PHARMA
Dec-13
GLENMARK PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs7123,063-   
Low Rs4842,661-   
Sales per share (Unadj.) Rs349.61,758.1-  
Earnings per share (Unadj.) Rs32.8109.8-  
Cash flow per share (Unadj.) Rs44.3251.9-  
Dividends per share (Unadj.) Rs2.0096.14-  
Dividend yield (eoy) %0.33.4 10.0%  
Book value per share (Unadj.) Rs198.61,952.9-  
Shares outstanding (eoy) m282.17848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.71.6 105.0%   
Avg P/E ratio x18.226.1 69.9%  
P/CF ratio (eoy) x13.511.4 118.7%  
Price / Book Value ratio x3.01.5 205.3%  
Dividend payout %6.187.5 7.0%   
Avg Mkt Cap Rs m168,6252,427,154 6.9%   
No. of employees `00012.044.9 26.8%   
Total wages/salary Rs m20,5610-   
Avg. sales/employee Rs Th8,196.033,170.4 24.7%   
Avg. wages/employee Rs Th1,708.10-   
Avg. net profit/employee Rs Th768.52,072.1 37.1%   
INCOME DATA
Net Sales Rs m98,6551,490,844 6.6%  
Other income Rs m2,0810-   
Total revenues Rs m100,7361,490,844 6.8%   
Gross profit Rs m15,858408,269 3.9%  
Depreciation Rs m3,259120,506 2.7%   
Interest Rs m3,34629,283 11.4%   
Profit before tax Rs m11,335258,480 4.4%   
Minority Interest Rs m01,174 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672-169,678 -1.0%   
Tax Rs m3,756-3,156 -119.0%   
Profit after tax Rs m9,25093,132 9.9%  
Gross profit margin %16.127.4 58.7%  
Effective tax rate %33.1-1.2 -2,714.5%   
Net profit margin %9.46.2 150.1%  
BALANCE SHEET DATA
Current assets Rs m66,9681,006,911 6.7%   
Current liabilities Rs m40,211878,111 4.6%   
Net working cap to sales %27.18.6 313.9%  
Current ratio x1.71.1 145.2%  
Inventory Days Days8391 91.8%  
Debtors Days Days8196 84.7%  
Net fixed assets Rs m33,322486,943 6.8%   
Share capital Rs m2823,670 7.7%   
"Free" reserves Rs m55,7700-   
Net worth Rs m56,0521,656,045 3.4%   
Long term debt Rs m35,738762,302 4.7%   
Total assets Rs m132,8883,407,057 3.9%  
Interest coverage x4.49.8 44.6%   
Debt to equity ratio x0.60.5 138.5%  
Sales to assets ratio x0.70.4 169.7%   
Return on assets %9.53.6 263.8%  
Return on equity %16.55.6 293.4%  
Return on capital %17.84.9 361.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m40,1400-   
CASH FLOW
From Operations Rs m13,242237,563 5.6%  
From Investments Rs m-6,990-84,178 8.3%  
From Financial Activity Rs m-7,387-284,973 2.6%  
Net Cashflow Rs m-2,971-131,588 2.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 73.39 Rs / USD

Compare GLENMARK PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare GLENMARK PHARMA With: CIPLA  AJANTA PHARMA  SUVEN LIFESCIENCES  AUROBINDO PHARMA  FDC.  



Today's Market

Sensex Ends 163 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

It was indeed a volatile trading day for share markets in India today. After staging a gap-up opening, Indian share markets reversed gains.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

My Latest Stock Recommendation (Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC (Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now (Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer (Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More
-->

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

GLENMARK PHARMA SHARE PRICE


Oct 21, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - FRESENIUS KABI ONCO. COMPARISON

COMPARE GLENMARK PHARMA WITH

FEATURED VIDEOS

Why ITC and not HUL is my Idea of a Good Investment Right Now

Contrarian Trading in PSU Banks

Why I Asked My Subscribers to Sell Stocks and Move into Cash?

How to Save Money by Exiting Stocks Before They Fall

More Featured Videos

MARKET STATS